Bioxytran Inc BIXT

Healthcare Biotechnology

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

OTCQB:BIXT - Post by User

Bioxytran Inc

<< Previous

Bullboard Posts

Next >>

Post by amritadaniqueon Oct 25, 2023 10:00am

66 Views

Post# 35699876

$BIXT: Transforming Healthcare with Innovation

Bioxytran, Inc. ($BIXT) is a leading force in healthcare innovation, with a remarkable market capitalization exceeding $24.5 million and solid support from over 144 million outstanding shares. Their strong 30-day average volume of 146,489 indicates growing interest in their pioneering medical solutions. The previous closing price of $0.17 highlights their potential and influence in the industry.

<< Previous

Bullboard Posts

Next >>

Mastering options Greeks: Essential knowledge for informed trading